Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Sector Summary: The Healthcare sector (+0.54%) is trading higher today, in-line w/ the S&P 500 (+0.47%)<strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>Zosano Pharma (<strong>ZSAN</strong> +71.67%) announces its lead product candidate, M207, achieved both co-primary endpoints of pain freedom and most bothersome symptom freedom at 2 hours in the recently completed ZOTRIP trial</li><li>XOMA (<strong>XOMA</strong> +17.12%) agrees to sell 1,200,000 shares of its common stock and 5,003 shares of convertible preferred stock directly to Biotechnology Value Fund, L.P. and certain of its affiliates; BVF agreed to purchase the shares of common stock from the Co pursuant to a subscription agreement at a price of $4.03/share</li><li>SAGE Therapeutics (<strong>SAGE</strong> +12.78%) announces 'encouraging' top-line results from its Phase 2 clinical trial of orally-administered SAGE-217 for the treatment of major depressive disorder; study 'demonstrates positive signal of activity and tolerability'</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>Signal Genetics (<strong>SGNL</strong> -19.31%) stockholders approved all of the merger-related proposals including the issuance of common stock, note conversion and reverse stock split</li><li>XTL Biopharma (<strong>XTLB</strong> -9.59%) Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome</li><li>Axovant Sciences (<strong>AXON</strong> -5.13%) announces preliminary results from the planned interim analysis of the first 11 patients to complete its Phase 2 study of nelotanserin in Lewy body dementia patients; Beneficial treatment effect observed on the pre-specified primary endpoint of Unified Parkinson's Disease Rating Scale Parts II + III</li></ul><strong><span style="color:#228822;">Gainers on earnings:</span></strong><br/> <ul><li>Teva Pharma (<strong>TEVA</strong> +4.01%) beats by $0.02, beats on revs; reaffirms FY17 EPS and rev guidance</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>BioLineRx (<strong>BLRX</strong> +9.17%) initiated with a Buy at Rodman & Renshaw; tgt $3</li><li>Capricor Therapeutics (<strong>CAPR</strong> +4.17%) assumed with a Buy at Rodman & Renshaw; tgt $14</li><li>Arch Therapeutics (<strong>ARTH</strong> +3.54%) initiated with a Buy at Rodman & Renshaw; tgt $2.50</li><li>Masimo (<strong>MASI</strong> -1.09%) downgraded to Mkt Perform from Outperform at Raymond James</li></ul></td> </tr></table>"